# FDA warns 30 telehealth firms over compounded GLP-1 ads

> On March 3, 2026, FDA announced 30 warning letters to telehealth firms over claims that compounded GLP-1s match approved drugs or hide who makes them.

- Canonical URL: https://livingpluspeptides.com/news/fda-warns-telehealth-compounded-glp1/
- Last updated: October 26, 2026
- Publisher: Living+

Published October 26, 2026.

On March 3, 2026, FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products on their websites [1]. GLP-1 drugs include [semaglutide](/peptides/semaglutide/) and [tirzepatide](/peptides/tirzepatide/) [1, 2].

## What the letters cited

FDA named two main problems [1]:

- Claims that implied a compounded product is the same as an FDA-approved drug [1].
- Products sold under the telehealth company's own name or trademark without qualification, which suggests the company is the compounder and hides where the drug comes from [1].

FDA called this the second group of warning letters to telehealth firms since it began a crackdown on misleading direct-to-consumer drug ads the previous September [1]. It said it had sent thousands of letters over six months asking drug and telehealth firms to remove misleading ads [1].

## Why sameness claims matter

FDA's release restates the basic rule: compounded drugs are not FDA-approved, FDA does not review their safety, effectiveness or quality before they are marketed, and they are not the same as generic drugs, which are FDA-approved [1]. FDA's earlier GLP-1 statement lays out how its compounding policies changed once the semaglutide and tirzepatide shortages ended [2]. For a side-by-side look, see [compounded vs FDA-approved semaglutide](/compare/compounded-vs-fda-approved-semaglutide/) and the guide [how peptides are prescribed in the US](/guides/how-peptides-are-prescribed/) [1, 2].

## Sources

1. [FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026)](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s)
2. [FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)

Educational information, not medical advice. This site sells nothing.